非小细胞肺癌中KAI1/CD82和CD44的表达水平与患者临床病理特征之间的关系

Relationship between the levels of KAI1/CD82 and CD44 and the clinicopathological features of non-small cell lung cancer

目的 观察KAI1/CD82和CD4 4蛋白在肺癌组织中的表达水平与患者临床病理特征的关系。方法 应用流式细胞仪 ,对 4 5例肺癌患者 (肺癌组 )手术切除的新鲜癌组织标本和癌旁 3cm组织 (对照组 1)、癌旁 5cm组织 (对照组 2 )及 30例肺部良性病变组织 (对照组 3)中KAI1/CD82和CD4 4表达水平进行检测 ,并结合患者的临床病理资料对其结果进行对比分析。结果 肺癌组中KAI1/CD82表达水平低于其他 3组 (P <0 .0 1) ,CD4 4表达水平高于其他 3组 (P <0 .0 1) ;对照组 1中KAI1/CD82表达水平低于对照组 2和对照组 3(P <0 .0 5 ) ,CD4 4表达水平高于对照组 2和对照组3(P <0 .0 5 )。KAI1/CD82和CD4 4表达水平在对照组 3和对照组 2之间差异均无显著性 (P >0 .0 5 )。KAI1/CD82和CD4 4表达水平与肺癌患者临床分期、组织分化程度和淋巴结转移密切相关 (P <0 .0 1) ,但在不同性别、年龄、肿块大小和病理类型的患者之间其表达水平差异无显著性 (P >0 .0 5 )。肿瘤原发灶中KAI1/CD82表达水平高于转移灶 ,而CD4 4表达水平低于转移灶 (P <0 .0 1)。KAI1/CD82蛋白表达水平与肺癌临床分期和淋巴结转移呈负相关 (P <0 .0 1) ;CD4 4蛋白表达水平与其呈正相关 ;两种蛋白的表达水平呈负相关 (P <0 .0 1)。结论 KAI1/CD82和CD4 4表达?

Objective To observe the relationship between levels of KAI1/CD82 and CD44 in lung carcinomas and their clinicopathological features, in association with the results of metastasis. Methods The expressions of KAI1/CD82 and CD44 in 45 patients with lung cancer were detected by flow-cytometry. Tissue samples 3 cm (control group 1) and 5 cm (control group 2) from the cancerous lesions and benign lesions from 30 patients (control group 3) were also studied, and the results were compared. Results The expression level of KAI1/CD82 protein in lung cancer was lower than that in other three groups( P <0.01), while the expression level of CD44 was higher than that in other three groups( P <0.01). The expression level of KAI1/CD82 in control group 1 was also lower than that in control group 2 and benign lesion group ( P <0.05). The expression level of CD44 was higher than that in control group 2 and benign lesion group( P <0.05). There was no significant difference between the expression level of CD44 and KAI1/CD82 in control group 2 and benign lesion group( P >0.05).The expression level of KAI1/CD82 and CD44 were closely correlated with clinical staging, pathological differentiation and lymph node metastasis( P <0.01), but their expressions were not correlated with sex, age, tumor size and pathological type( P >0.05). Statistic difference was found between KAI1/CD82 and CD44 in primary lesions and metastatic lesions ( P <0.01). There was an inversely correlation between the expression of CD44 and KAI1/CD82 in clinical staging and lymph node metastasis ( P <0.01). Conclusion KAI1/CD82 and CD44 may play an important regulating role in the genesis, development and metastasis of lung cancer, and they may be used as potential markers for tumor metastasis.